Date: 2011-01-28
Type of information: Halting of the trial
phase: 3
Announcement: halting of the clinical development
Company: Actelion (Switzerland)GSK (UK)
Product: Almorexant
Action
mechanism: Almorexant is a dual orexin receptor antagonist
Disease: primary insomnia
Therapeutic area: CNS diseases - Neurological diseases
Country:
Trial
details: * On January 28,2011, GSK and Actelion announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the clinical profile of almorexant, including the tolerability profile.
GSK and Actelion remain committed to conducting further research to better understand the potential of orexin receptor antagonism in sleep disorders and other indications. Both companies will continue to work on the discovery and development of new orexin receptor antagonist therapies, based on the orexin alliance formed in July 2008.
Latest news:
